BerandaGBM • FRA
add
Inovio Pharmaceuticals Inc
Tutup sebelumnya
€3,80
Rentang hari
€3,85 - €3,85
Rentang tahun
€3,69 - €12,14
Kapitalisasi pasar
108,14Â jt USD
Volume Rata-Rata
105,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 27,35Â jt | 175,54% |
Laba bersih | -25,17Â jt | 25,83% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,89 | 42,95% |
EBITDA | -26,93Â jt | -10,37% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 84,80Â jt | -49,36% |
Total aset | 107,06Â jt | -44,56% |
Total liabilitas | 33,52Â jt | -38,99% |
Total ekuitas | 73,54 jt | — |
Saham yang beredar | 26,10 jt | — |
Harga terhadap nilai buku | 1,35 | — |
Tingkat pengembalian aset | -56,77% | — |
Tingkat pengembalian modal | -69,87% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -25,17Â jt | 25,83% |
Kas dari operasi | -27,44Â jt | 5,73% |
Kas dari investasi | 14,08Â jt | 356,25% |
Kas dari pembiayaan | 660,65Â rb | -5,44% |
Perubahan kas bersih | -12,70Â jt | 62,53% |
Arus kas bebas | -17,47Â jt | 10,73% |
Tentang
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
Didirikan
1999
Situs
Karyawan
127
